ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

NCT03338816 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Hepatic Porphyria
Acute Intermittent Porphyria
Porphyria, Acute Intermittent
Acute Porphyria
Hereditary Coproporphyria (HCP)
Variegate Porphyria (VP)
ALA Dehydratase Deficient Porphyria (ADP)

Interventions

DRUG: Givosiran
DRUG: Placebo

Sponsor

Alnylam Pharmaceuticals